Literature DB >> 22699010

Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence.

Christine A Clark, Carl A Laskin, Karen A Spitzer.   

Abstract

In 1987, Nigel Harris cautioned against over-diagnosing the antiphospholipid syndrome (APS). In what was a rather prophetic editorial titled 'The Syndrome of the Black Swan', he suggested that while patients with APS do indeed exist, they are probably much more unusual than many medical professionals might like to believe. He expressed concern that the value of studying antiphospholipid antibodies (aPLs) as interesting non-organ specific autoantibodies, would become lost in a 'sea of over-interpreted and over-reported laboratory and clinical findings'. It is our contention that 25 years later, this prediction has come to pass, particularly with respect to one type of aPL and its relation to a clinical event, namely anticardiolipin antibodies and early recurrent pregnancy loss. In this commentary, we trace the evolution of the current dogma and propose that reevaluation of available data from an alternative perspective results in quite a different understanding, the acceptance of which would necessitate not only a revision of the classification criteria for APS but also the subsequent revision of many diagnoses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699010     DOI: 10.1093/humupd/dms020

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  8 in total

1.  What's new in obstetric antiphospholipid syndrome.

Authors:  D Ware Branch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Thrombophilia screening in women with recurrent first trimester miscarriage: is it time to stop testing? - a cohort study and systematic review of the literature.

Authors:  Hassan Shehata; Amanda Ali; Mariane Silva-Edge; Shahla Haroon; Abdullatif Elfituri; Radhika Viswanatha; Haider Jan; Ranjit Akolekar
Journal:  BMJ Open       Date:  2022-07-13       Impact factor: 3.006

3.  Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes.

Authors:  May Ching Soh; Dharmintra Pasupathy; Gabriella Gray; Catherine Nelson-Piercy
Journal:  Rheumatology (Oxford)       Date:  2013-05-16       Impact factor: 7.580

4.  Preconception antiphospholipid antibodies and risk of subsequent early pregnancy loss.

Authors:  K J Gibbins; S L Mumford; L A Sjaarda; D W Branch; N J Perkins; A Ye; E F Schisterman; R M Silver
Journal:  Lupus       Date:  2018-05-17       Impact factor: 2.911

5.  Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes.

Authors:  Polona Žigon; Katja Perdan Pirkmajer; Matija Tomšič; Tanja Kveder; Borut Božič; Snežna Sodin Šemrl; Saša Čučnik; Aleš Ambrožič
Journal:  J Immunol Res       Date:  2015-05-20       Impact factor: 4.818

Review 6.  Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome.

Authors:  Martin Killian; Thijs E van Mens
Journal:  Front Cardiovasc Med       Date:  2022-03-01

7.  Anti-Phosphatidylserine/Prothrombin Antibodies in Healthy Women with Unexplained Recurrent Pregnancy Loss.

Authors:  Daniel E Pleguezuelo; Oscar Cabrera-Marante; Magdalena Abad; Edgard Alfonso Rodriguez-Frias; Laura Naranjo; Alicia Vazquez; Olga Villar; Francisco Javier Gil-Etayo; Manuel Serrano; Alfredo Perez-Rivilla; Laura de la Fuente-Bitaine; Antonio Serrano
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

8.  Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study.

Authors:  Rosalía Demetrio Pablo; Pedro Muñoz Cacho; Marcos López-Hoyos; Vanesa Calvo-Río; Leyre Riancho-Zarrabeitia; Víctor M Martínez-Taboada
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-03       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.